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The use of antibodies is widespread in many areas including in-vivo and in-vitro 
diagnostics, quantitative analysis in research laboratories and as therapeutic substances. 
Since the methods for generation of antibodies has improved and regularly results in 
high-affinity interactions, the standard assays used for quantification of the interaction 
properties should be revisited because they do not necessarily produce accurate results. 
Here we show that in several cases, the affinity determination of strongly binding 
antibodies will be inherently difficult when using standard procedures, due to 
impractically long incubation times. Real-time kinetic analysis is often the only realistic 
alternative for affinity determination. 
 
The estimate of how strongly an antibody binds to its antigen is often reported as the 
affinity, KD, of the interaction. The affinity can be measured using a variety of assays, 
most requiring that the reading takes place when equilibrium has occurred. The increased 
focus on high-affinity antibodies (typically KD <1 nM) has led to a situation where the 
time to equilibrium increases vastly. The essence of reading at equilibrium is seldom 
discussed, and the appropriateness of protocols developed for normal affinity antibodies 
are often taken for granted. Conducting assays before reaching equilibrium can result in 
false negative results1 and the importance of sufficiently long incubation times has been 
discussed in the context of DNA microarrays2, immunohistochemistry3 and drug-receptor 
interactions4. There are however still a wide-spread use of inappropriate protocols where 
too short incubation times may generate confusing or inaccurate results. 
 
Time to equilibrium (T) depends on three parameters: the association rate (ka), the 
dissociation rate (kd) and the antibody concentration (C), according to the approximate 
expression4 T ≈ 3.5/(ka*C + kd) (s). Figure 1 shows simulations of how four different 
monovalent interactions with different affinity and kinetic properties would perform in an 
immunofluorescense assay with different incubation times. Two examples were 
generated for the affinity 1 nM, one fast on fast off interaction representing an average 
antibody interaction and one slow on slow off representing a relatively good antibody. 
The fast interaction would be accurately quantified at incubation times beyond three 
hours, while as the slow interaction would require over-night incubation to reach 
equilibrium and produce accurate results. At higher affinities, which are common for 
therapeutic antibodies and other optimized binding proteins, incubation time exceeding 
10 hours is required for reasonable accuracy in the immunofluorescense assay. Incubation 
time will in particular increase to many hours at slower dissociation rate i.e. kd less than 
approximately 10-5s-1. Even if an assay is interrupted prematurely, the read data will look 
like a good affinity determination. When using such results to estimate affinity, the 
produced values may differ more than two orders of magnitude compared to the true 
value, as seen in figure 1D. 
 
In practice, the time to equilibrium for therapeutic antibodies may well be longer than 24 
hours. Figure 2 shows the temporal progress of pertuzumab binding to the HER2 receptor 
on SKOV3 cells and cetuximab binding to the EGF receptor on U343 cells as measured 
using LigandTracer Green5. The antibody was titrated in three steps; 0.44 nM, 1.3 nM 
and finally 4.4 nM, followed by a dissociation measurement. It is clear that even at 4.4 
nM, which is greater than KD in both cases, more than 20 hours are required to reach 
equilibrium. These two antibodies bind to their targets with high-affinity, albeit not in 
any extreme manner. 
 
In some cases these errors can be devastating, in particular when comparison of 
molecular properties should be conducted. In competitive assays where one compound is 
preincubated, insufficient preincubation time may cause incomplete competition and 
generate confusing results1. Furthermore, when using the concept of microdosing with 
PET tracers to test substances in man during early phases of drug development, the 
effects of high affinity and low concentration in relation to time to equilibrium has also to 
be considered for obtaining relevant results6. In other cases, such as immunoassay 
formats for concentration determination based on standards, short incubation time may 
not be any serious complication. 
 
It is not always possible to use sufficiently long incubation times. In particular in cell 
based assays the cells may metabolize the antibody if incubating too long. Thus, the 
preferred alternative is to follow the interaction in real time, and use the curvature of the 
binding event for estimation of binding kinetics and affinity. This has been done for 
protein-protein interactions since the advent of SPR based real-time biosensors7 and is a 
robust method for estimating the affinity. SPR based techniques are however usually 
limited to dissociation rates greater than 10-5s-1 and cannot be used for cell-based assays. 
This is now possible with new technology equipment that produce similar real-time 
binding traces that can be used for kinetic based affinity determinations and for receptor 
density on cells5. 
 
In conclusion, the search for high-affinity antibodies implies that the basic requirements 
for the assays used to quantify antibody-antigen interactions should be revised. Particular 
focus should be put on ensuring that the interaction is given sufficient time to reach 
equilibrium, where it is required. Alternative assays that do not require equilibrium exist, 
and are feasible alternatives for accurate quantification of high-affinity interactions. 
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Online methods 
 
Monoclonal antibody trastuzumab (purified from Herceptin®, Roche AB, Stockholm, 
Sweden) was labeled with fluorescein isothiocyanate (FITC, Thermo Fisher Scientific 
Inc., Waltham, MA, USA) according to the manufacturers protocol. Monoclonal antibody 
cetuximab (purified from Erbitux®, Merck KGaA, Darmstadt, Germany) was labeled 
with Alexa Fluor ® 488 (Invitrogen, Carlsbad, CA, USA) according to the manufacturers 
protocol. The human ovarian carcinoma cell line SKOV3 (HTB-77, ATCC, Rocksville, 
MD, USA) known to express HER2 and the human glioma cell line U343MGaCl2:6 
(denoted U343) known to express EGFR were used for interaction analysis. The cells 
were grown at 37ºC in incubator with humidified atmosphere and 5 % CO2 in Ham´s F10 
cell culture medium (Biochrom AG, Berlin, Germany) supplemented with 10 % fetal calf 
serum (FCS, Sigma, St Louis, MO, USA), PEST (penicillin 100 IU/ml and streptomycin 
100 µg/ml, Biochrom AG, Berlin, Germany) and L-glutamin (2 nM). The cells were 
seeded on a small local area of a petri dish (Nuclon™, dish size 100x20, NUNC A/S, 
Roskilde, Denmark) as described previously [Björke and Andersson, 2005] . 
LigandTracer® Green was used to monitor the interaction of [trastuzumab-FITC] – 
HER2 on SKOV3 cells and [cetuximab-AlexaFluor488] – EGFR on U343 cells, 
essentially as described previously [Björke and Andersson, 2005]. The antibody 
concentration was titrated during continuous monitoring of the antibody-antigen 
interaction: First 0.44 nM during three hours, then 1.3 nM during four hours, and finally 
4.4 nM during 17 hours. After the incubation with antibody, the cell dish was emptied 
and measured during four hours with fresh cell-culture medium (devoid of antibody) to 
show antibody dissociation. 
 
 
Figure Legends 
 
Figure 1. Theoretical binding assay results for four different interactants at five different 
incubation times. The legend in section A applies to all four sections in the figure. A: 
KD=1 nM, ka=105 M-1s-1, kd=10-4 s-1, B: KD=1 nM, ka=104 M-1s-1, kd=10-5 s-1, C: KD=0.1 
nM, ka=105 M-1s-1, kd=10-5 s-1, D: KD=30 pM, ka=105 M-1s-1, kd=3×10-6 s-1. 
 
Figure 2. Two therapeutic antibodies interacting with their targets on living cells, 
monitored in real-time using LigandTracer Green. Red curve shows [trastuzumab-FITC] 
– HER2 on SKOV3 cells and black curve shows [cetuximab-AlexaFluor488] – EGFR on 
U343 cells. 


